Cargando…
Eliminating viral hepatitis C in Belgium: the micro-elimination approach
BACKGROUND: Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (n = 64,000) in 2015. Although Belgium has had a ‘Hepatitis C Plan’ s...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045456/ https://www.ncbi.nlm.nih.gov/pubmed/32106819 http://dx.doi.org/10.1186/s12879-020-4898-y |
_version_ | 1783501778819481600 |
---|---|
author | Busschots, Dana Toghanian, Samira Bielen, Rob Salomonsson, Stina Koc, Özgür M. Hendrickx, Greet Jadoul, Michel Nevens, Frederik Sokal, Etienne Brixko, Christian Peerlinck, Kathelijne Apers, Ludwig Robaeys, Geert Lazarus, Jeffrey V. |
author_facet | Busschots, Dana Toghanian, Samira Bielen, Rob Salomonsson, Stina Koc, Özgür M. Hendrickx, Greet Jadoul, Michel Nevens, Frederik Sokal, Etienne Brixko, Christian Peerlinck, Kathelijne Apers, Ludwig Robaeys, Geert Lazarus, Jeffrey V. |
author_sort | Busschots, Dana |
collection | PubMed |
description | BACKGROUND: Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (n = 64,000) in 2015. Although Belgium has had a ‘Hepatitis C Plan’ since 2014, elimination efforts are unclear. This study employs the best available data and modelling estimates to define the burden of hepatitis C viral infection among key subgroups in Belgium, identify information gaps and propose potential approaches to screening, linkage to care and treatment, and cure. METHODS: We examined the peer-reviewed and grey literature since 2012 for data on the prevalence of hepatitis C viral infection in Belgium in key subgroups identified by national experts and in the literature. Ultimately, this research is primarily based on data provided by the key stakeholders themselves due to a lack of reliable data in the literature. Based on this, we modelled the treatment rates required to reach elimination of hepatitis C in several subgroups. RESULTS: Eleven potential subgroups were identified. There were no data available for two subgroups: generational cohorts and men who have sex with men. In six subgroups, fewer than 3000 people were reported or estimated to have hepatitis C infection. Migrants and people who inject drugs were the most affected subgroups, and children were the least affected subgroup. Only two subgroups are on target to achieve elimination by 2030: patients living with haemophilia and transplant recipients. CONCLUSIONS: Removing Belgian treatment reimbursement restrictions in January 2019 was a big step towards eliminating HCV. In addition, increasing surveillance, including with a national registry, treatment prescription by other health-care providers and availability of treatment in local pharmacies are central to improving the current situation and getting on track to reach the 2030 WHO hepatitis C elimination targets in Belgium. |
format | Online Article Text |
id | pubmed-7045456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70454562020-03-03 Eliminating viral hepatitis C in Belgium: the micro-elimination approach Busschots, Dana Toghanian, Samira Bielen, Rob Salomonsson, Stina Koc, Özgür M. Hendrickx, Greet Jadoul, Michel Nevens, Frederik Sokal, Etienne Brixko, Christian Peerlinck, Kathelijne Apers, Ludwig Robaeys, Geert Lazarus, Jeffrey V. BMC Infect Dis Research Article BACKGROUND: Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (n = 64,000) in 2015. Although Belgium has had a ‘Hepatitis C Plan’ since 2014, elimination efforts are unclear. This study employs the best available data and modelling estimates to define the burden of hepatitis C viral infection among key subgroups in Belgium, identify information gaps and propose potential approaches to screening, linkage to care and treatment, and cure. METHODS: We examined the peer-reviewed and grey literature since 2012 for data on the prevalence of hepatitis C viral infection in Belgium in key subgroups identified by national experts and in the literature. Ultimately, this research is primarily based on data provided by the key stakeholders themselves due to a lack of reliable data in the literature. Based on this, we modelled the treatment rates required to reach elimination of hepatitis C in several subgroups. RESULTS: Eleven potential subgroups were identified. There were no data available for two subgroups: generational cohorts and men who have sex with men. In six subgroups, fewer than 3000 people were reported or estimated to have hepatitis C infection. Migrants and people who inject drugs were the most affected subgroups, and children were the least affected subgroup. Only two subgroups are on target to achieve elimination by 2030: patients living with haemophilia and transplant recipients. CONCLUSIONS: Removing Belgian treatment reimbursement restrictions in January 2019 was a big step towards eliminating HCV. In addition, increasing surveillance, including with a national registry, treatment prescription by other health-care providers and availability of treatment in local pharmacies are central to improving the current situation and getting on track to reach the 2030 WHO hepatitis C elimination targets in Belgium. BioMed Central 2020-02-27 /pmc/articles/PMC7045456/ /pubmed/32106819 http://dx.doi.org/10.1186/s12879-020-4898-y Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Busschots, Dana Toghanian, Samira Bielen, Rob Salomonsson, Stina Koc, Özgür M. Hendrickx, Greet Jadoul, Michel Nevens, Frederik Sokal, Etienne Brixko, Christian Peerlinck, Kathelijne Apers, Ludwig Robaeys, Geert Lazarus, Jeffrey V. Eliminating viral hepatitis C in Belgium: the micro-elimination approach |
title | Eliminating viral hepatitis C in Belgium: the micro-elimination approach |
title_full | Eliminating viral hepatitis C in Belgium: the micro-elimination approach |
title_fullStr | Eliminating viral hepatitis C in Belgium: the micro-elimination approach |
title_full_unstemmed | Eliminating viral hepatitis C in Belgium: the micro-elimination approach |
title_short | Eliminating viral hepatitis C in Belgium: the micro-elimination approach |
title_sort | eliminating viral hepatitis c in belgium: the micro-elimination approach |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045456/ https://www.ncbi.nlm.nih.gov/pubmed/32106819 http://dx.doi.org/10.1186/s12879-020-4898-y |
work_keys_str_mv | AT busschotsdana eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT toghaniansamira eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT bielenrob eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT salomonssonstina eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT kocozgurm eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT hendrickxgreet eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT jadoulmichel eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT nevensfrederik eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT sokaletienne eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT brixkochristian eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT peerlinckkathelijne eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT apersludwig eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT robaeysgeert eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach AT lazarusjeffreyv eliminatingviralhepatitiscinbelgiumthemicroeliminationapproach |